Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists

Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists

Disclosed are pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists for example 2-CHLORO-4-[1-(4-FLUORO-PHENYL)-2,5-DIMETHYL-1H-IMIDAZOL-4-YLETHYNYL]-PYRIDINE or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: HUANG JINGJUN, SHAH NAVNIT HARGOVINDAS, LINDENSTRUTH KAI, KOENNINGS STEPHANIE, CHATTERJI ASHISH, SANDHU HARPREET K
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Disclosed are pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists for example 2-CHLORO-4-[1-(4-FLUORO-PHENYL)-2,5-DIMETHYL-1H-IMIDAZOL-4-YLETHYNYL]-PYRIDINE or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active compound with a rate-controlling polymer and a pH responding polymer, binder and fillers in either matrix pellet, matrix tablet or coated pellets. The compositions provide a pH-independent release profile with NMT 70 % in one hour, NMT 85 % in 4 hour, and NLT 80 % in 8 hours. The compositions are useful for the treatment of CNS disorders, such as Treatment- Resistant Depression (TRD) and Fragile X Syndrome.